Publication Topic

Enayetallah AE, Ziemek D, Leininger MT, Randhawa R, Yang J, Manion TB, Mather DE,…, Greene N, et al. 2011. Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform. PLoS One 6(11):e27009; doi: 10.1371/journal.pone.0027009. PMID: 22073239.

Thompson CM, Proctor DM, Haws LC, Hebert CD, Grimes SD, Shertzer HG, Kopec AK, Hixon JG, Zacharewski TR, Harris MA. 2011. Investigation of the mode of action underlying the tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium. Toxicol Sci 123(1):58-70; doi: 10.1093/toxsci/kfr164. PMID: 21712504.

Proctor D, Haws L, Thompson C, Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

Hinerman J, Herr A. Determining the mechanism of activation of glycoprotein VI. Poster presented to the Ohio Valley Crystallographic Symposium Meeting, Cleveland, OH, November 2011.

Proctor D, Meek B. Using mode of action data to guide quantitative cancer risk assessment: A case study of hexavalent chromium in drinking water. Presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

Thompson CM, Haws LC, Harris MA, Gatto NM, Proctor DM. 2011. Application of the U.S. EPA mode of action framework for purposes of guiding future research: A case study involving the oral carcinogenicity of hexavalent chromium. Toxicol Sci 119(1):20-40; doi: 10.1093/toxsci/kfq320. PMID: 20947717.

Proctor DM, Gatto NM, Hong SJ, Allamneni KP. 2007. Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment. Toxicol Sci 98(2):313–326; doi: 10.1093/toxsci/kfm075. PMID: 17426108.

Urban JD, Jin J, Mailman RB. 2006. N27 dopaminergic cell line: A useful model for studying the mechanisms of action of functionally selective dopaminergic compounds. Society for Toxicology 45th Annual Meeting, San Diego, CA, March 2006.